Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA.
Am J Obstet Gynecol. 2010 Sep;203(3):261.e1-5. doi: 10.1016/j.ajog.2010.05.029. Epub 2010 Jul 14.
We sought to investigate the effect of body mass index (BMI) on in vitro response to tocolytics.
Myometrial biopsies were obtained at the time of scheduled cesarean deliveries from term nonlaboring women with BMI < or =29.9 (26.3 +/- 1.3; n = 7), 30-34.9 (31.8 +/- 1.2; n = 16), and > or = 35 (39.5 +/- 4.9; n = 9). Tissue strips were suspended in organ chambers for isometric tension recording. The effects of cumulative doses (10(-10) to 10(-5) mol/L) of nifedipine or indomethacin on spontaneous uterine contractility were determined. Areas under the contraction curve were compared using 1-way analysis of variance with Tukey post hoc test.
Myometrial response to tocolytics did not differ between the BMI groups. Nifedipine, but not indomethacin, significantly inhibited myometrial contractility independent of BMI.
BMI does not affect uterine response to tocolytics in isolated uterine tissue from term nonlaboring women.
我们旨在研究体重指数（BMI）对宫缩抑制剂体外反应的影响。
从 BMI <或=29.9（26.3 +/- 1.3；n = 7）、30-34.9（31.8 +/- 1.2；n = 16）和 >或= 35（39.5 +/- 4.9；n = 9）的足月非临产妇女的择期剖宫产术中获得子宫活检。组织条在等长张力记录器官室中悬挂。确定累积剂量（10(-10) 至 10(-5) mol/L）的硝苯地平或吲哚美辛对自发性子宫收缩性的影响。使用单因素方差分析和 Tukey 事后检验比较收缩曲线下面积。
BMI 组之间宫缩抑制剂的子宫反应没有差异。硝苯地平而非吲哚美辛显著抑制了与 BMI 无关的子宫收缩性。
BMI 不影响足月非临产妇女离体子宫组织对宫缩抑制剂的子宫反应。
